- Home
- TLPH vs NXTC Comparison
TLPH vs NXTC Comparison
Compare TLPH & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- NXTC
- Stock Information
- Founded
- TLPH 2005
- NXTC 2015
- Country
- TLPH United States
- NXTC United States
- Employees
- TLPH N/A
- NXTC N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- NXTC Health Care
- Exchange
- TLPH Nasdaq
- NXTC Nasdaq
- Market Cap
- TLPH 11.1M
- NXTC 13.0M
- IPO Year
- TLPH 2011
- NXTC 2019
- Fundamental
- Price
- TLPH $0.94
- NXTC $5.55
- Analyst Decision
- TLPH Strong Buy
- NXTC Strong Buy
- Analyst Count
- TLPH 1
- NXTC 2
- Target Price
- TLPH $6.00
- NXTC $25.50
- AVG Volume (30 Days)
- TLPH 4.3M
- NXTC 13.3K
- Earning Date
- TLPH 11-12-2025
- NXTC 11-06-2025
- Dividend Yield
- TLPH N/A
- NXTC N/A
- EPS Growth
- TLPH N/A
- NXTC N/A
- EPS
- TLPH N/A
- NXTC N/A
- Revenue
- TLPH $27,000.00
- NXTC N/A
- Revenue This Year
- TLPH N/A
- NXTC N/A
- Revenue Next Year
- TLPH $14,533.26
- NXTC N/A
- P/E Ratio
- TLPH N/A
- NXTC N/A
- Revenue Growth
- TLPH N/A
- NXTC N/A
- 52 Week Low
- TLPH $0.38
- NXTC $2.69
- 52 Week High
- TLPH $1.20
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- TLPH 75.75
- NXTC 59.97
- Support Level
- TLPH $0.88
- NXTC $5.19
- Resistance Level
- TLPH $1.20
- NXTC $5.90
- Average True Range (ATR)
- TLPH 0.13
- NXTC 0.28
- MACD
- TLPH 0.03
- NXTC 0.07
- Stochastic Oscillator
- TLPH 62.70
- NXTC 69.03
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.